Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma

This study is testing a triple combination of immunotherapy drugs — adebrelimab and camrelizumab (two immune checkpoint inhibitors) plus apatinib (a drug that blocks blood vessel growth) — as a first-line treatment for people with advanced hepatocellular carcinoma (HCC), the most common type of liver cancer that cannot be removed with surgery or local treatment. **You may be eligible if:** - You are 18 or older - You have been diagnosed with advanced or metastatic liver cancer (hepatocellular carcinoma) confirmed by biopsy or established imaging criteria, and surgery or local treatment is not possible — or your cancer has progressed after surgery or local treatment - You are able to provide tumor tissue samples - Your organ function and overall health are adequate for treatment - Side effects from any previous local treatment (like radiation or ablation) have resolved **You may NOT be eligible if:** - You have active uncontrolled infections or severe other medical conditions - Your liver function is significantly impaired - You have received prior systemic (whole-body) anti-cancer therapy that would disqualify you - You do not meet organ function requirements Talk to your doctor to see if this trial is right for you.